-
IMMUNEX CORPORATION et al v. SANDOZ INC. et al DC CAFC
- 2:16-cv-01118
- D.N.J.
- Filed: 02/26/2016
- Closed: 10/08/2019
- Latest Docket Entry: 07/23/2021
- Judge: Claire C. Cecchi
+1
- PACER
3
Plaintiffs
3
Defendants
1
Accused
Product
5
Patents-in-Suit
1,321
Days in
Litigation
-
IMMUNEX CORPORATION et al v. SANDOZ INC. et al DC CAFC
- 2:16-cv-01118
- D.N.J.
- Filed: 02/26/2016
- Closed: 10/08/2019
- Latest Docket Entry: 07/23/2021
- Judge: Claire C. Cecchi
+1
- PACER
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
11 |
The protein of claim 1, wherein the protein consists essentially of the extracellular region of the insoluble human TNF receptor and all the domains of the constant region of a human IgG<sub>1 </sub>immunoglobulin heavy chain other than the first
view more
|
Enforceable and Valid
Entry 719 |
12 |
A pharmaceutical composition comprising the protein of claim 11 and a pharmaceutically acceptable carrier material.
|
Enforceable and Valid
Entry 719 |
35 |
The protein of claim 30, wherein the protein consists essentially of the extracellular region of the human tumor necrosis factor (TNF) receptor amino acid sequence encoded by the cDNA insert, and all the domains of the constant region of a human
view more
|
Enforceable and Valid
Entry 719 |
36 |
A pharmaceutical composition comprising the protein of claim 35 and a pharmaceutically acceptable carrier material.
|
Enforceable and Valid
Entry 719 |
Claim # | Claim Text | Outcome |
---|---|---|
3 |
The method of claim 1, wherein the IgG heavy chain is an IgG<sub>1 </sub>heavy chain.
|
Enforceable and Valid
Entry 719 |
8 |
The method of claim 7, wherein the human IgG immunoglobulin heavy chain is an IgG<sub>1 </sub>heavy chain.
|
Enforceable and Valid
Entry 719 |
10 |
The method of claim 8, wherein the host cell is a CHO cell.
|
Enforceable and Valid
Entry 719 |
-
Infringement
Sandoz GmbH
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic etanercept product | US 8,063,182 B1 |
11, 12, 35, 36
|
Infringement
Entry 719
|
Generic etanercept product | US 8,163,522 B1 |
3, 8, 10
|
Infringement
Entry 719
|
Sandoz Inc.
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic etanercept product | US 8,063,182 B1 |
11, 12, 35, 36
|
Infringement
Entry 719
|
Generic etanercept product | US 8,163,522 B1 |
3, 8, 10
|
Infringement
Entry 719
|
Sandoz International GmbH
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic etanercept product | US 8,063,182 B1 |
11, 12, 35, 36
|
Infringement
Entry 719
|
Generic etanercept product | US 8,163,522 B1 |
3, 8, 10
|
Infringement
Entry 719
|